Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma

BMC Immunology

Andrey Tchorbanov¹  Krassimira Idakieva²  Lyuba Doumanova¹  Iliyan Manoylov¹  Nikolina Mihaylova¹  Stela Chausheva¹  Vera Gesheva¹ 

[1] The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. 26, Sofia, 1113, Bulgaria;Institute of Organic Chemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 9, Sofia, 1113, Bulgaria

关键词: Anti-cancer activity;    Hemocyanins;    Helix pomatia;    Rapana thomasiana;    Murine cancer model;    C-26 carcinoma;   

Others  :  1077708
DOI  :  10.1186/s12865-014-0034-3

 received in 2014-03-24, accepted in 2014-08-21,  发布年份 2014

【 摘 要 】

Background

Various immunotherapeutic approaches have been used for the treatment of cancer. A number of natural compounds are designed to repair, stimulate, or enhance the immune system response. Among them are the hemocyanins (Hcs) - extracellular copper proteins isolated from different arthropod and mollusc species. Hcs are oxygen transporter molecules and normally are freely dissolved in the hemolymph of these animals. Hemocyanins are very promising class of anti-cancer therapeutics due to their immunogenic properties and the absence of toxicity or side effects. KLH (Megathura crenulata hemocyanin) is the most studied molecule of this group setting a standard for natural carrier protein for small molecules and has been used in anti-tumor clinical trials.

Results

The Hcs isolated from marine snail Rapana thomasiana (RtH) and the terrestrial snail Helix pomatia (HpH) express strong in vivo anti-cancer and anti-proliferative effects in the developed by us murine model of colon carcinoma. The immunization with RtH and HpH prolonged the survival of treated animals, improve humoral anti-cancer response and moderate the manifestation of C-26 carcinoma symptoms as tumor growth, splenomegaly and lung metastasis appearance.

Conclusion

Hemocyanins are used so far for therapy of superficial bladder cancer and murine melanoma models. Our findings demonstrate a potential anti-cancer effect of hemocyanins on a murine model of colon carcinoma suggesting their use for immunotherapy of different types of cancer.

【 授权许可】

   
2014 Gesheva et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Vanneman M, Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
• [2]Morales A, Eidinger D, Bruce A: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116:180-183.
• [3]Alexandroff A, Jackson A, O’Donnell M, James K: BCG immunotherapy is used to prevent and treat superficial bladder cancer. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999, 353:1689-1694.
• [4]Scott A, Wolcho J, Old L: Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
• [5]Lee S, Margolin K: Cytokines in cancer immunotherapy. Cancer 2011, 3:3856-3893.
• [6]Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F, Verjee S, Jones L, Hershberg R: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
• [7]Sabbatini P, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, Spassova M, Zatorski A, Spriggs D, Aghajanian C, Soignet S, Peyton M, O’Flaherty C, Curtin JO, Lloyd K: Immunization of ovarian cancer patients with a synthetic lewisy-protein conjugate vaccine: clinical and serological results. Int J Cancer 2000, 87:79-85.
• [8]Ragupathi G, Slovin S, Adluri S, Sames D, Kim IJ, Kim HM, Spassova M, Bornmann WG, Lloyd KO, Scher HI, Livingston PO, Danishefsky SJ: A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew Chem Int Ed Engl 1999, 38:563-566.
• [9]Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, Livingston PO: Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 1995, 41:185-192.
• [10]Bhatnagar I, Kim SK: Marine antitumor drugs: status, shortfalls and strategies. Mar Drugs 2010, 8:2702-2720.
• [11]Wang YQ, Miao ZH: Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs 2013, 11:903-933.
• [12]Van Holde KE, Miller KI: Hemocyanins. Adv Protein Chem 1995, 47:1-8.
• [13]Harris JR, Markl J: Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999, 30:597-623.
• [14]Markl J, Lieb B, Gebauer W, Altenhein B, Meissner U, Harris JR: Marine tumor vaccine carriers: structure of the molluscan hemocyanins KLH and HtH. J Cancer Res Clin Oncol 2001, 127:R3-R9.
• [15]Rizvi I, Riggs DR, Jackson BJ, McFadden DW: Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo. Am J Surg 2007, 194:628-632.
• [16]Arancibia S, Campo M, Nova E, Salazar F, Becker M: Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects. Eur J Immunol 2012, 42:688-699.
• [17]Tchorbanov A, Idakieva K, Mihaylova N, Doumanova L: Modulation of the immune response using Rapana thomasiana hemocyanin. Int Immunopharmacol 2008, 8:1033-1038.
• [18]Gesheva V, Idakieva K, Kerekov N, Nikolova K, Mihaylova N, Doumanova L, Tchorbanov A: Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins. Fish Shellfish Immunol 2011, 30:135-142.
• [19]Preaux G, Gielens C: Hemocyanins. In Cooper Proteins and cooper enzymes. Edited by Lontie R. CRC Press, Boca Raton; 1984:159-205.
• [20]Corbett TH, Griswold DP, Roberts BJ Jr, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975, 35:2434-2439.
• [21]Cheng K, Koeck P, Elmund H, Idakieva K, Parvanova K, Schwarz H, Ternström T, Hebert H: Rapana thomasiana hemocyanin (RtH): comparison of the two isoforms, RtH1 and RtH2, at 19 Å and 16 Å resolution. Micron 2006, 37:566-576.
• [22]Perbandt M, Guthöhrlein E, Rypniewski W, Idakieva K, Stoeva S, Voelter W, Genov N, Betzel C: The structure of a functional unit from the wall of a Gastropod hemocyanin offers a possible mechanism for cooperativity. Biochemistry 2003, 42:6341-6346.
• [23]Idakieva K, Stoeva S, Voelter W, Gielens C: Glycosylation of Rapana thomasiana Hemocyanin. Comparison with Other Prosobranch (Gastropod) Hemocyanins. Comp Biochem Physiol 2004, 138B:221-228.
• [24]Livingston PO, Zhang S, Lloyd K: Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 1997, 45:1-9.
• [25]Wirguin I, Suturkova Milosevic L, Briani C, Latov N: Keyhole limpet hemocyanin contains Gal (b 1–3)-GalNAc determinants that are cross-reactive with the T antigen. Cancer Immunol Immunother 1995, 40:307-310.
• [26]Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S, Coletti D: Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. Cancer 2010, 10:1-15.
• [27]Riggs DR, Jackson B, Vona-Davis L, McFadden D: In Vitro Anticancer Effects of a Novel Immunostimulant: Keyhole Limpet Hemocyanin. J Surg Res 2002, 108:279-284.
• [28]McFadden DW, Riggs DR, Jackson BJ, Vona-Davis L: Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett’s esophageal adenocarcinoma. Am J Surg 2003, 186:552-555.
• [29]Idakieva K, Severov S, Svendsen I, Genov N, Stoeva S, Beltramini M, Tognon G, Di Muro P, Salvato B: Structural properties of Rapana thomasiana hemocyanin: isolation, characterization and N-terminal amino acid sequence of two different dissociation products. Comp Biochem Physiol 1993, 106B:53-59.
• [30]Heirwegh K, Borginon H, Lontie R: Separation and absorption spectra of α-and β-haemocyanin of Helix pomatia. Biochim Biophys Acta 1961, 48:517-526.
• [31]Gielens C, Verschueren LJ, Preґaux G, Lontie R: Gel chromatographic separation of the haemocyanins of Helix pomatia. Further electrophoretic and immunological characterization of the components. Comp Biochem Physiol 1981, 69B:455-462.
• [32]Idakieva K, Schwartz H, Genov N, Voelter W, Stoeva S: Rapana thomasiana hemocyanin (RtH): Dissociation and reassociation behaviour of two isoforms. RtH1 and RtH2. Micron 2002, 33:7-14.
• [33]Wood EJ, Chaplin MF, Gielens C, De Sadeleer J, Preaux G, Lontie R: Relative molecular mass of the polypeptide chain of βc-haemocyanin of Helix pomatia and carbohydrate composition of the functional units. Comp Biochem Physiol B 1985, 82:179-186.